Roger Laparra, InésEstornut Navarro, CristinaMontero, PaulaAparici, MónicaPuig, CarlosDavis, Andre M.Albericio, FernandoDiego, Alfredo deMilara, JavierCortijo, Julio2026-04-092026-04-092026Roger, I., Estornut, C., Montero, P., Aparici, M., Puig, C., Davis, A. M., Albericio, F., De Diego, A., Milara, J., & Cortijo, J. (2026). Targeting the Keap1-Nrf2 Axis in COPD: Comparative analysis of electrophilic and peptide-based Nrf2 activators in airway and immune cells. European Journal of Pharmacology, 1019, 178716. https://doi.org/10.1016/j.ejphar.2026.1787160014-29991879-0712https://hdl.handle.net/11268/17015Chronic obstructive pulmonary disease (COPD) is characterized by sustained oxidative stress, inflammation, and epithelial damage. The transcription factor Nrf2 is a master regulator of antioxidant and cytoprotective defenses, and its dysregulation has been implicated in COPD pathogenesis.engBiocienciasEnfermedad Pulmonar Obstructiva CrónicaActivación NeutrófilaSistema Inmunológicojournal article10.1016/j.ejphar.2026.178716embargoed accessInmunologíaAparato respiratorioInvestigación médicaGoal 3: Ensure healthy lives and promote well-being for all at all ages